|
Synonyms: 4(1MeW) [2] | POT-4
Compound class:
Peptide or derivative
Comment: AL-78898A is an investigational analogue of compstatin [2], which acts as an irreversible inhibitor of complement component 3 (C3). C3 inhibitors are being actively investigated for clinical potential in inflammatory and degenerative diseases [1].
|
| No information available. |
Summary of Clinical Use  |
| AL-78898A (POT4) has been investigated i Phase 2 clinical trial for neovascular age-related macular degeneration (AMD). Click here to link to ClinicalTrials.gov's list of AL-78898A/POT-4 trials. See F1000Prime Rep. 2014; 6: 29 (Advances in the management of macular degeneration) for a review of recent research and development in this field. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Prevents activation of C3, the central component mediating activation of the classical, alternative, and lectin pathways of complement activation. |
